Q32 Bio Inc.
A maker of biologic medicines that calm an overactive immune system, Q32 Bio develops antibody treatments for autoimmune and inflammatory diseases. Its lead drug candidate, bempikibart, is being studied for alopecia areata, an autoimmune condition that causes hair loss. The Waltham, Massachusetts company began in 2017 as AdMIRx and renamed itself Q32 Bio in 2020 — a name it has never publicly explained.
Bought 625.0K
Sold 2.19M
Sold 2.19M
Bought 1.88M
Bought 1.88M
Bought 1.78M · Sold 1.67M
Granted 250.0K
Bought 375.0K
Bought 250.0K
Granted 264.0K · Sold 52.7K
Sold 16.0K
Granted 98.9K · Sold 8.6K
Granted 20.1K · Sold 102.3K
Granted 106.5K · Sold 21.3K
Granted 37.5K
Granted 93.6K · Sold 79.4K
Granted 10.8K
Granted 7.6K
Granted 81.4K · Sold 141.8K
Granted 6.9K · Sold 2.0K
Granted 4.3K · Sold 1.7K
Granted 51.7K · Sold 18.5K
Granted 12.6K · Sold 20.5K
Granted 10.7K · Sold 1.8K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Fullerton Management Pte Ltd +4 co-filers10% owner · 3 transactions | — | 7.42Mas of Apr 2018 | — | 625.0K | — |
| Gillis StevenDirector · 1 transaction | — | 6.07Mas of Apr 2018 | — | — | — |
| Bybee Clinton +6 co-filers10% owner · 2 transactions | — | 5.77Mas of May 2019 | — | — | — |
| Diekman John D +5 co-filers10% owner · 15 transactions | — | 4.54Mas of Dec 2020 | — | — | 2.19M |
| Parmar KushDirector · 15 transactions | — | 4.54Mas of Dec 2020 | — | — | 2.19M |
| Orbimed Advisors LLC +2 co-filersDirector, 10% owner · 2 transactions | — | 4.13M | — | 1.88M | — |
| Xu DiyongDirector, 10% owner · 2 transactions | — | 4.13M | — | 1.88M | — |
| Deerfield Management Company, L.P. (Series C) +7 co-filersReporting owner · 20 transactions | — | 4.09Mas of Jan 2020 | — | 1.78M | 1.67M |
| Novartis Ag +1 co-filer10% owner · 1 transaction | — | 1.98Mas of Apr 2018 | — | — | — |
| Shah MahendraDirector · 1 transaction | — | 909.7Kas of Apr 2018 | 250.0K | — | — |
| VV Manager LLC +1 co-filer10% owner · 2 transactions | — | 770.8Kas of Apr 2018 | — | 375.0K | — |
| Rock Springs Capital LLC +2 co-filers10% owner · 2 transactions | — | 645.8Kas of Apr 2018 | — | 250.0K | — |
| Morrison Jodie PopeCEO, Director · 6 transactions | — | 343.3K | 264.0K | — | 52.7K |
| Rasty SiyamakChief Operating Officer · 2 transactions | — | 222.7Kas of Jul 2019 | — | — | 16.0K |
| Violette Shelia M.Chief Scientific Officer · 8 transactions | — | 164.0K | 98.9K | — | 8.6K |
| Seymour AlbertSee Remarks, Director · 19 transactions | — | 150.9Kas of Sep 2023 | 20.1K | — | 102.3K |
| Kalowski LeeCFO and President · 6 transactions | — | 138.5K | 106.5K | — | 21.3K |
| Campagna JasonChief Medical Officer · 1 transaction | — | 37.5Kas of Feb 2025 | 37.5K | — | — |
| Smith W BradfordSee Remarks · 26 transactions | — | 14.2Kas of Jan 2023 | 93.6K | — | 79.4K |
| Gregory Richard J.Director · 1 transaction | — | 10.8Kas of Nov 2019 | 10.8K | — | — |
| Blum Michael LeeChief Commercial Officer · 2 transactions | — | 9.4Kas of Jan 2023 | 7.6K | — | — |
| Tzianabos ArthurDirector · 20 transactions | — | 8.0Kas of Mar 2024 | 81.4K | — | 141.8K |
| Jordan JulieChief Medical Officer · 8 transactions | — | 4.2Kas of Aug 2023 | 6.9K | — | 2.0K |
| Cohn GabrielChief Medical Officer · 2 transactions | — | 2.6Kas of Jan 2022 | 4.3K | — | 1.7K |
| Alloway PaulSee Remarks · 9 transactions | — | 2.6Kas of Mar 2024 | 51.7K | — | 18.5K |
| Kelly Timothy PChief Operating Officer · 17 transactions | — | 2.2Kas of Jan 2022 | 12.6K | — | 20.5K |
| Michaud Charles JrSee Remarks · 6 transactions | — | 927as of Mar 2024 | 10.7K | — | 1.8K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: +271.4K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.